Aclarion, Inc. (ACON) Stock Score, Valuation & Financial Research
Aclarion, Inc. is in the Healthcare sector and Medical - Healthcare Information Services industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 10/100.
Quick answer for ACON
Aclarion, Inc. currently has a Wall Street Score of 10/100. The stored market price is $2.6. Its financial score is 40/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Aclarion, Inc. does
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
ACON financial snapshot
- Wall Street Score:
- 10/100
- Current price:
- $2.6
- Market capitalization:
- $1.4M
- Revenue:
- $84K
- Net income:
- $-9.2M
- Free cash flow:
- $-7.2M
- Cash:
- $16.3M
- Total debt:
- $0
- EPS:
- -7.60
- Financial score:
- 40/100
- Valuation score:
- 0/100
- Revenue score:
- 11/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-7.2M, showing cash burn in the current stored period.
- The balance sheet shows $16.3M of cash versus $0 of total debt, leaving more cash than debt.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 40/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ACON
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.